GlassScriptPhysician profile
William J Bjerregaard
NPI 1043207806
$12,012.53
in general payments reported to CMS, 2019-2025
33 companies · $3,672 in 2025
The $3,672 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,278 · 2020: $465 · 2022: $88.36 · 2023: $2,318 · 2024: $3,190 · 2025: $3,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,163 · Education: $17.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,163.13 |
| Education | $17.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,068.39 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $977.17 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $976.38 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $854.36 | 2023-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $680.16 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $659.90 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $632.00 | 2019-2025 | Trintellix |
| Almatica Pharma LLC | $618.68 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $510.69 | 2023-2025 | Auvelity |
| Abbvie INC. | $478.85 | 2023-2025 | Vraylar, Lumigan |
| Supernus Pharmaceuticals, INC. | $472.33 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $458.11 | 2023-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $435.90 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $433.91 | 2019-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $408.88 | 2019-2025 | Fanapt, Hetlioz |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $407.23 | 2019-2020 | |
| Neos Therapeutics, LP | $345.71 | 2019-2024 | Adzenys Xr-Odt |
| Shire North American Group INC | $291.24 | 2019 | |
| Ironshore Pharmaceuticals INC. | $245.75 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $176.52 | 2023 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $145.58 | 2025 | Jornay Pm |
| Allergan, INC. | $100.11 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $96.10 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $83.30 | 2024 | Secuado, Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $83.28 | 2024-2025 | Cobenfy |
| Owp Pharmaceuticals, INC. | $70.83 | 2019-2020 | |
| Rhodes Pharmaceuticals L.P. | $68.66 | 2019 | |
| Avanir Pharmaceuticals, INC. | $64.95 | 2019 | |
| Adlon Therapeutics L.P. | $54.04 | 2019-2020 | |
| Sage Therapeutics, LLC | $46.18 | 2024 | |
| Neuronetics, INC. | $28.60 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.68 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $14.06 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bjerregaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.